This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Neurocutaneous Diseases  • Women's Health  • Women's Health, Other  • Drug Therapy  • Adverse Effects  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Joel Moss, MD,PhD; Rosamma DeCastro, MSN,CRNP; Nicolas J. Patronas, MD; Angelo Taveira-DaSilva, MD,PhD

JAMA. 2001;286:1879-1881.

Context  Lymphangioleiomyomatosis (LAM), a cystic lung disease associated with progressive respiratory failure, is found predominantly in women of childbearing age and therefore has been treated with progesterone and other hormonal agents. However, meningiomas have progesterone receptors, and progesterone is believed to be a mitogen for meningioma cells in culture. Since 30% to 40% of patients with tuberous sclerosis complex (TSC) have LAM, we routinely screen patients with LAM for brain lesions found in TSC.

Objective  To determine the prevalence of meningiomas in women with LAM.

Design and Setting  Analysis of results from ongoing routine screening protocols initiated in December 1995 at the National Heart, Lung, and Blood Institute.

Patients  Two hundred fifty women with sporadic LAM who were referred for screening by magnetic resonance imaging (MRI) and/or computed tomography (CT) of the brain.

Main Outcome Measures  Presence of meningiomas on MRI and/or CT scans.

Results  Eight women with LAM (3 with and 5 without a diagnosis of TSC) had lesions on MRI scans compatible with meningiomas. Five of the patients had been treated with progesterone. Multiple meningiomas were observed in 2 patients.

Conclusions  Women with LAM appear to have a high prevalence of meningiomas. We recommend that patients with LAM be screened for meningiomas regardless of diagnosis of TSC. In view of the lack of a documented effect of progesterone on progression of lung disease in LAM and the reported mitogenic response of meningiomas to progesterone, we recommend that the drug not be given to LAM patients with an MRI result consistent with diagnosis of meningioma.

Author Affiliations: Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute (Drs Moss and Taveira-DaSilva and Ms DeCastro), and Department of Diagnostic Radiology, Clinical Center (Dr Patronas), National Institutes of Health, Bethesda, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Meningiomas in Women With Lymphangioleiomyomatosis
David Neal Franz, Joel Moss, Rosamma DeCastro, Angelo Taveira-DaSilva, and Nicolas J. Patronas
JAMA. 2002;287(11):1397-1398.
EXTRACT | FULL TEXT  

RELATED ARTICLE

October 17, 2001
JAMA. 2001;286(15):1911-1912.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Is There an Association Between Meningioma and Hormone Replacement Therapy?
Blitshteyn et al.
JCO 2008;26:279-282.
ABSTRACT | FULL TEXT  

Lymphangioleiomyomatosis.
Johnson
Eur Respir J 2006;27:1056-1065.
ABSTRACT | FULL TEXT  

Decline in Lung Function in Patients With Lymphangioleiomyomatosis Treated With or Without Progesterone
Taveira-DaSilva et al.
Chest 2004;126:1867-1874.
ABSTRACT | FULL TEXT  

Should patients with lymphangioleiomyomatosis undergo screening for meningioma?
Cottin et al.
Eur Respir J 2004;24:888-889.
FULL TEXT  

Meningiomas in Women With Lymphangioleiomyomatosis
Franz et al.
JAMA 2002;287:1397-1398.
FULL TEXT